Tesaro Files for $86M IPO to Advance CINV Drug Rolapitant

Tesaro Inc. continued its stellar trajectory, filing an S-1 registration statement with the SEC seeking to raise up to $86.3 million in an initial public offering (IPO) to advance rolapitant, its selective neurokinin-1 (NK1) receptor antagonist with an extended plasma half-life.